Here, we describe a step in this direction by means of an analytical model and topology-based algorithms that quantify relationships between scientific discoveries and cures.
We established and automated data collection and network analysis protocols utilizing publicly accessible databases, including www.fda.gov, www. clinicaltrials.gov, www.pubmed.gov, and www.webofknowledge.com. In a pilot study, we considered the recently successful applications for regulatory approval of two new drugs: ipilimumab in oncology and ivacaftor for cystic fibrosis. These medical advances are sufficiently novel and important to be reasonably characterized as ''cures'' (vide supra) . Ipilimumab is the first successful entry into the new and burgeoning field of immunooncology (Sharma and Allison, 2015) by which sustained clinical remissions are being induced in patients with previously intractable cancers by releasing immune effector cells from checkpoint inhibition. Ivacaftor corrects the structure of a specific loss-of-function mutation in the cystic fibrosis transmembrane conductance regulator and is the first targeted therapy of this heritable disease. Beginning with the references cited in clinical trials and information provided to the U.S. Federal Drug Administration (FDA) for regulatory approval of these drugs (FDA, 2011; FDA, 2012) , we extracted two consecutive rounds of retrospective citations and constructed network models of articles, authors, and institutions contributing to the network. Assumptions underlying this approach are: (1) that the authors of FDA applications and clinical trials will appropriately cite publications reporting new knowledge critical to the development of a new drug candidate and (2) that further retrospective rounds of citations will identify previous discoveries that were most important in establishing the base of knowledge that enabled the successful drug development program.
We learned that the nature of a cure discovery citation network is complex and fundamentally collaborative with respect to the number of different scientists and institutions making contributions to a cure. For example, the citation network leading to ipilimumab includes 7,067 different scientists who listed 5,666 different institutional and departmental affiliations and includes discoveries spanning 104 years of research ( Figure 1A ). Results for ivacaftor are similar: 2,857 different scientists from 2,516 different institutional and departmental affiliations, with discoveries spanning 59 years of research ( Figure 1B) .
We next characterized individual scientists within each citation network by two metrics. Propagated in-degree rank (PIR) is based on the number and citation count of articles that a given author published within the citation network and is a measure of influence within this selective set of publications. Ratio of basic rankings (RBR) is based on how selectively a given author published within the cure discovery citation network relative to background networks of topically related publications similar in size, scope, and structure. This ratio helps to normalize their overall publication output.
By applying the metrics of PIR and RBR to the entire cure discovery citation network, the most influential and selective contributors to these massive networks emerge. Thus, in the case of ipilimumab, 15 scientists and 7 institutions associated with 433 articles spanning 46 years are characterized as elite performers ( Figure 1A and Table S1 ). Elite performers within the ivacaftor network exhibiting similar properties as defined by the same metrics include 33 scientists and 7 institutions associated with 355 articles spanning 47 years ( Figure 1B and Table  S1 ). These elite performer subnetworks are integral to their overall citation networks, serving as hubs for 31% of the ipilimumab network and 49% of the ivacaftor network.
These data quantify how the knowledge base on which important advances in medicine (''cures'') depend includes contributions from a large and diverse set of individual scientists working in many locales. This insight should be instructive for policy makers by suggesting that future cures will depend on broadly based public support of life sciences. Narrowly targeted funding initiatives may well have value but are unlikely in isolation to generate the breadth of new knowledge required to lay the foundation for future cures.
We call on the scientific community to embrace and advance the concept of cure network informatics so as to develop advanced and sophisticated analytical tools to increase understanding of how scientific discoveries lead to cures, including predictive metrics that may guide decision making with respect to work in progress. All of the code necessary to reproduce and extend this initial effort is freely available and open source (Lotia and Pico, 2015) . This network informatics approach can be applied to any ''cure'' with a cited publication trail. Curators of publically available databases could play important roles in these efforts by considering cure network informatics in the design of database architecture and embedded tools. It will be important to identify trends that hold across all cures and ones that are specific to certain types of cures. It will also be useful to identify features of hubs within cure networks that are essential to the flow of knowledge required to create a cure.
A need for better metrics for assessing performance and for decision support within the life sciences is widely acknowledged by leaders and commentators in biomedicine (Sarli and Carpenter, 2014; University of Gothenburg, 2013) . Metrics that are readily understandable by nonscientists, grounded in outcomes that the general public values highly (cures),
and faithful to what scientists know to be the richly intersecting and often unpredictable nature of scientific discovery should be more useful for influencing policy makers than currently available alternatives. Further development of new and useful tools for cure network informatics should contribute to increased public trust in, and support for, the life science enterprise. Table S1 ), their articles, and their institutions are highlighted in yellow with red connecting lines.
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